Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “intravitreal”

16 pharma patents match "intravitreal" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 16
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 16 pharmaceutical patents matching "intravitreal" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

16 results for “intravitreal” · 30,257 patents in full index Clear search

  1. US 12331099

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted

  2. US 11732024

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted

  3. US 11084865

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 10, 2021 · Expires Aug 5, 2041

    granted

  4. US 11066458

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 20, 2021 · Expires Jul 15, 2041

    granted

  5. US 10464992

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted

  6. US 10400025

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2019 · Expires Aug 29, 2039

    granted

  7. US 9914763

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 13, 2018 · Expires Mar 8, 2038

    granted

  8. US 9580489

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 28, 2017 · Expires Feb 23, 2037

    granted

  9. US 9340594

    VEGF antagonist formulations for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted May 17, 2016 · Expires May 12, 2036

    granted

  10. US 8802107

    VEGF antagonist formulations for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 12, 2014 · Expires Aug 7, 2034

    granted

  11. US 8481046

    VEGF antagonist formulations for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  12. US 8420619

    Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein

    Ceregene, Inc. · Granted Apr 16, 2013 · Expires Apr 11, 2033

    granted

  13. US 8242093

    Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein

    Ceregene, Inc. · Granted Aug 14, 2012 · Expires Aug 9, 2032

    granted

  14. US 8092803

    VEGF antagonist formulations for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 10, 2012 · Expires Jan 5, 2032

    granted

  15. US 7807164

    Lyophilized VEGF antagonist formulations for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 5, 2010 · Expires Sep 30, 2030

    granted

  16. US 7608261

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 27, 2009 · Expires Oct 22, 2029

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.